402 related articles for article (PubMed ID: 28776311)
1. Continued EGFR-TKI with concurrent radiotherapy to improve time to progression (TTP) in patients with locally progressive non-small cell lung cancer (NSCLC) after front-line EGFR-TKI treatment.
Wang Y; Li Y; Xia L; Niu K; Chen X; Lu D; Kong R; Chen Z; Sun J
Clin Transl Oncol; 2018 Mar; 20(3):366-373. PubMed ID: 28776311
[TBL] [Abstract][Full Text] [Related]
2. Concurrent EGFR-TKI and Thoracic Radiotherapy as First-Line Treatment for Stage IV Non-Small Cell Lung Cancer Harboring EGFR Active Mutations.
Zheng L; Wang Y; Xu Z; Yang Q; Zhu G; Liao XY; Chen X; Zhu B; Duan Y; Sun J
Oncologist; 2019 Aug; 24(8):1031-e612. PubMed ID: 31040256
[TBL] [Abstract][Full Text] [Related]
3. Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors.
Chen Q; Quan Q; Ding L; Hong X; Zhou N; Liang Y; Wu H
Oncotarget; 2015 Sep; 6(28):24904-11. PubMed ID: 26172562
[TBL] [Abstract][Full Text] [Related]
4. Synergistic effects of metformin in combination with EGFR-TKI in the treatment of patients with advanced non-small cell lung cancer and type 2 diabetes.
Chen H; Yao W; Chu Q; Han R; Wang Y; Sun J; Wang D; Wang Y; Cao M; He Y
Cancer Lett; 2015 Dec; 369(1):97-102. PubMed ID: 26341687
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib.
Lee VH; Leung DK; Choy TS; Lam KO; Lam PM; Leung TW; Kwong DL
BMC Cancer; 2016 Feb; 16():147. PubMed ID: 26911310
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy of salvage chemotherapy in the advanced non-small cell lung cancer patients who failed the treatment of chemotherapy and EGFR-TKI].
Fan Y; Huang ZY; Yu HF; Luo LH
Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):859-63. PubMed ID: 21223694
[TBL] [Abstract][Full Text] [Related]
7. Postoperative survival of EGFR-TKI-targeted therapy in non-small cell lung cancer patients with EGFR 19 or 21 mutations: a retrospective study.
Yang W; Gao Y; Li X; Zhang J; Liu T; Feng X; Pan H; Yang X; Xie S; Feng X; Lv Z; Wang Y; Chen Z; He J
World J Surg Oncol; 2017 Nov; 15(1):197. PubMed ID: 29110716
[TBL] [Abstract][Full Text] [Related]
8. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
9. T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients.
Li W; Ren S; Li J; Li A; Fan L; Li X; Zhao C; He Y; Gao G; Chen X; Li S; Shi J; Zhou C; Fei K; Schmid-Bindert G
Lung Cancer; 2014 Jun; 84(3):295-300. PubMed ID: 24685306
[TBL] [Abstract][Full Text] [Related]
10. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
[TBL] [Abstract][Full Text] [Related]
11. Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer.
Komaki R; Allen PK; Wei X; Blumenschein GR; Tang X; Lee JJ; Welsh JW; Wistuba II; Liu DD; Hong WK
Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):317-24. PubMed ID: 25968826
[TBL] [Abstract][Full Text] [Related]
12. Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease.
Kashiwabara K; Semba H; Fujii S; Tsumura S
Cancer Chemother Pharmacol; 2017 Apr; 79(4):705-710. PubMed ID: 28258422
[TBL] [Abstract][Full Text] [Related]
13. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
[TBL] [Abstract][Full Text] [Related]
14. EGFR-tyrosine kinase inhibitor treatment beyond progression in long-term Caucasian responders to erlotinib in advanced non-small cell lung cancer: a case-control study of overall survival.
Faehling M; Eckert R; Kamp T; Kuom S; Griese U; Sträter J; Ott G; Spengler W
Lung Cancer; 2013 Jun; 80(3):306-12. PubMed ID: 23489557
[TBL] [Abstract][Full Text] [Related]
15. Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain.
Arriola E; García Gómez R; Diz P; Majem M; Martínez Aguillo M; Valdivia J; Paredes A; Sánchez-Torres JM; Peralta Muñoz S; Barneto I; Gutierrez V; Andrade Santiago JM; Aparisi F; Isla D; Ponce S; Vicente Baz D; Artal A; Amador M; Provencio M
BMC Cancer; 2018 Jan; 18(1):106. PubMed ID: 29382302
[TBL] [Abstract][Full Text] [Related]
16. RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation.
Yoshida T; Yoh K; Niho S; Umemura S; Matsumoto S; Ohmatsu H; Ohe Y; Goto K
Lung Cancer; 2015 Dec; 90(3):477-83. PubMed ID: 26604031
[TBL] [Abstract][Full Text] [Related]
17. Impact of Continuing First-Line EGFR Tyrosine Kinase Inhibitor Therapy Beyond RECIST Disease Progression in Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer (NSCLC): Retrospective GFPC 04-13 Study.
Auliac JB; Fournier C; Audigier Valette C; Perol M; Bizieux A; Vinas F; Decroisette Phan van Ho C; Bota Ouchlif S; Corre R; Le Garff G; Fournel P; Baize N; Lamy R; Vergnenegre A; Arpin D; Marin B; Chouaid C; Gervais R
Target Oncol; 2016 Apr; 11(2):167-74. PubMed ID: 26315967
[TBL] [Abstract][Full Text] [Related]
18. Clinical Characteristics and Continued Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Administration in EGFR-mutated Non-Small Cell Lung Cancer with Skeletal Metastasis.
Hong SH; Kim YS; Lee JE; Kim IH; Kim SJ; Han D; Yoo IeR; Chung YG; Kim YH; Lee KY; Kang JH
Cancer Res Treat; 2016 Jul; 48(3):1110-9. PubMed ID: 26790969
[TBL] [Abstract][Full Text] [Related]
19. Prolonged survival of patients with EGFR-mutated non-small cell lung cancer with solitary brain metastases treated with surgical resection of brain and lung lesions followed by EGFR TKIs.
Gui Q; Liu J; Li D; Xu C
World J Surg Oncol; 2017 Oct; 15(1):184. PubMed ID: 29037198
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of concurrent versus sequential icotinib therapy and chemotherapy in advanced non-small cell lung cancer with sensitive EGFR mutations.
Zhang Y; Wang J; Yu Z; Ge H; Zhang LW; Feng LX
Clin Transl Sci; 2021 May; 14(3):890-897. PubMed ID: 33382908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]